Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of long-term odronextamab treatment in patients with relapsed/refractory follicular lymphoma: 3-year follow-up from the Phase 2 ELM-2 study

Jose Villasboas Bisneto, Deepa Jagadeesh, Don Stevens, Michal Taszner, Jingxian Cai, Amulya Uppala, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Manjusha Namuduri, Geoffrey Chong

Blood (2025) 146 (Supplement 1): 3588.

https://doi.org/10.1182/blood-2025-3588

Published: 2025

Journal Articles

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Blood (2025) 146 (Supplement 1): 5514.

https://doi.org/10.1182/blood-2025-5514

Published: 2025

Journal Articles

Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003

Philippe Armand, Seung Tae Lee, Wojciech Jurczak, Don Stevens, Sylvain Choquet, Herve Ghesquieres, Lalita Norasetthada, Antonio Pinto, Güray Saydam, Heng Zhou, Nishitha Reddy, Rushdia Yusuf, Muhit Ozcan

Blood (2025) 146 (Supplement 1): 3745.

https://doi.org/10.1182/blood-2025-3745

Published: 2025

Journal Articles

Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY

Paolo Ghia, Barbara Eichhorst, Tomasz Wrobel, Inci Alacacıoğlu, Ana Rita da Fonseca, Dennis Carney, Guillaume Cartron, Alina Gerrie, Don Stevens, Marianne de Borja, Toshifumi Fujimori, Ellie John, L. Alex Liggett, Gary De Jesus, Veerendra Munugalavadla, Jennifer Brown

Blood (2025) 146 (Supplement 1): 3898.

https://doi.org/10.1182/blood-2025-3898

Published: 2025

Journal Articles

First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study

Blood (2025) 146 (Supplement 1): 3730.

https://doi.org/10.1182/blood-2025-3730

Published: 2025

Journal Articles

Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial

Blood (2025) 146 (Supplement 1): 697.

https://doi.org/10.1182/blood-2025-697

Published: 2025

Journal Articles

Multicenter assessment of absolute neutrophil counts (ANC) and white blood cell counts (WBC) in healthy participants with the erythrocyte duffy null phenotype or genotype

Lauren Merz, Gilles Attipoe, Christina Barriteau, Michael Blechner, Eric Burks, Cecelia Calhoun, Sally Campbell Lee, Vivian Chang, Stella Chou, Adam Cuker, Emmanuel Fadeyi, Warren Fingrut, Victoria Forbes, Ivo Francischetti, Vijayakrishna Gadi, Richard Godby, Lucy Godley, Abraham Haimed, Hyojeong Han, Richard Haspel, Chibuzo Ilonze, Cyril Jacquot, Peng Ji, Justin Juskewitch, Matthew Karafin, Kimberly Klein, Nicole Kucine, Priya Kumar, Margarita Kushnir, David Levitz, Michael Lewis, Geling Li, Zhen Mei, Sabrina Racine Brzostek, Gary Rose, Corinna Schultz, Alexa Siddon, Christine Sillings, John Mark Sloan, Amy Soni, Don Stevens, Charlotte Story, James Szymanski, Clifford Takemoto, Alexis Thompson, Rahma Warsame, Angela Weyand, Samuel Wilson, Nibal Zaghloul, Yadashe Belay, Aliza Fink, Patricia Frustace, Jamie Tyson, Nathalie Van Havre, Maureen Okam Achebe

Blood (2025) 146 (Supplement 1): 1074.

https://doi.org/10.1182/blood-2025-1074

Published: 2025

Journal Articles

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Blood (2025) 146 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2025-1005

Published: 2025

Journal Articles

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study

David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, Don Stevens, Marc André, Ernesto Perez Persona, Petra Pichler, Philipp B. Staber, Marek Trneny, Johannes Duell, Maeve Waldron-Lynch, Steve Wagner, Amitava Mukhopadhyay, Maren Dirnberger-Hertweck, John M. Burke, Grzegorz S. Nowakowski

Blood (2023) 142 (16): 1348–1358.

https://doi.org/10.1182/blood.2023020637

Published: 2023

Includes: Supplemental data

Journal Articles

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

Blood (2021) 138 (Supplement 1): 1634.

https://doi.org/10.1182/blood-2021-146324

Published: 2021

Journal Articles

A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2

Sattva S. Neelapu, Mehdi Hamadani, Don Stevens, Sandra M. Hayes, Francesco Galimi, David B. Miklos

Blood (2021) 138 (Supplement 1): 2834.

https://doi.org/10.1182/blood-2021-147581

Published: 2021

Journal Articles

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Blood (2021) 138 (Supplement 1): 3793.

https://doi.org/10.1182/blood-2021-146003

Published: 2021

Journal Articles

First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study

Blood (2021) 138 (Supplement 1): 70.

https://doi.org/10.1182/blood-2021-148666

Published: 2021

Journal Articles

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy or in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Paul A. Hamlin, Manish R. Patel, Don Stevens, Brian T. Hess, Javier Munoz, Tatyana A. Feldman, Sonali M. Smith, Greg P. Coffey, Muhtarjan Osman, Jaymes S Holland, Cristina B Guzman, Stephen D. Smith

Blood (2021) 138 (Supplement 1): 2423.

https://doi.org/10.1182/blood-2021-148313

Published: 2021

Journal Articles

A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies

Manish R. Patel, Varun Monga, Shekeab Jauhari, Don Stevens, Lucia Masarova, Meredith McKean, David Mauro, John Viscusi, Peggy Scherle, Neha Bhagwat, Andrew Moore, William Sun, Rachel Chiaverelli, Eric Mintah, Rajneesh Nath, Eytan M. Stein, Neil Palmisiano, Grerk Sutamtewagul, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 2609.

https://doi.org/10.1182/blood-2021-150938

Published: 2021

Journal Articles

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Blood (2021) 138 (Supplement 1): 369.

https://doi.org/10.1182/blood-2021-150371

Published: 2021

Journal Articles

Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

John M. Burke, Gustavo Fonseca, Wojciech Jurczak, Jason Melear, Miguel Islas-Ohlmayer, James A Reeves, Parameswaran Venugopal, Tomasz Wróbel, Don Stevens, John M. Pagel, Jerome Goldschmidt, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Nilanjan Ghosh

Blood (2021) 138 (Supplement 1): 527.

https://doi.org/10.1182/blood-2021-151054

Published: 2021

Journal Articles

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

John E. Godwin, Bassam Mattar, Michael Maris, Carlos Bachier, Don Stevens, Daanish Hoda, Juan C. Varela, Mohamad Cherry, Suzanne Fanning, James Essell, Habte Yimer, Jay Courtright, Jeff P. Sharman, Ricardo Espinola, Connor Mailley, Ariel Avilion, Ken Ogasawara, San-San Ou, Paul Shaughnessy

Blood (2021) 138 (Supplement 1): 1762.

https://doi.org/10.1182/blood-2021-148792

Published: 2021

Journal Articles

ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T

Sattva S. Neelapu, Rajneesh Nath, Javier Munoz, Michael Tees, David B. Miklos, Matthew J. Frank, Shahbaz A. Malik, Don Stevens, Chu Ri Shin, Arun Balakumaran, Lynn Loomis-Navale, Lovely Goyal, Anh Nguyen, Frederick L. Locke

Blood (2021) 138 (Supplement 1): 3878.

https://doi.org/10.1182/blood-2021-146038

Published: 2021

Journal Articles

First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

David Belada, Katerina Kopeckova, Juan Miguel Bergua Burgues, Don Stevens, Marc André, Ernesto Pérez Persona, Petra Pichler, Philipp B. Staber, Marek Trneny, Bettina Brackertz, Neha Shah, Andrea Sporchia, John M. Burke, Grzegorz S. Nowakowski

Blood (2021) 138 (Supplement 1): 3556.

https://doi.org/10.1182/blood-2021-148354

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Efficacy and safety of long-term odronextamab treatment in patients with relapsed/refractory follicular lymphoma: 3-year follow-up from the Phase 2 ELM-2 study

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003

Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY

First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study

Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial

Multicenter assessment of absolute neutrophil counts (ANC) and white blood cell counts (WBC) in healthy participants with the erythrocyte duffy null phenotype or genotype

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study

Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd)

A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy or in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T

First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only